Rabeprazole
- Generic Name
- Rabeprazole
- Brand Names
- Aciphex, Pariet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N3O3S
- CAS Number
- 117976-89-3
- Unique Ingredient Identifier
- 32828355LL
- Background
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Develop NSAID-induced gastric ulcers, Erosive reflux esophagitis
- Associated Therapies
- -
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1061
- Registration Number
- NCT00658528
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1397
- Registration Number
- NCT00658632
Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1069
- Registration Number
- NCT00658775
Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 1142
- Registration Number
- NCT00614536
Open Label Study Evaluating Different Dosing Regimens of Rabeprazole in Gastro-esophageal Reflux Disease (GERD) Patients With Night-time Heartburn Symptoms.
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen-Ortho Inc., Canada
- Target Recruit Count
- 48
- Registration Number
- NCT00553449
Influence of Hygiene-dietetic Habits and Treatment Adherence on the Effectiveness of the Gastroesophageal Reflux Illness Treatment With Rabeprazol
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-08-06
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Janssen-Cilag, S.A.
- Target Recruit Count
- 1049
- Registration Number
- NCT00511966
A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg
- First Posted Date
- 2007-04-23
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Janssen-Cilag Pty Ltd
- Target Recruit Count
- 1392
- Registration Number
- NCT00464308
A Study to Monitor Intragastric pH in Patients Taking Rabeprazole vs. Patients Taking Pantoprazole
Phase 1
Completed
- Conditions
- First Posted Date
- 2006-09-19
- Last Posted Date
- 2012-12-10
- Lead Sponsor
- Janssen-Ortho Inc., Canada
- Target Recruit Count
- 37
- Registration Number
- NCT00378287
CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT00354757
- Locations
- 🇨🇳
National Taiwan Univeristy Hospital, Taipei, Taiwan
Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD
Phase 4
Completed
- Conditions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2007-09-17
- Lead Sponsor
- VA Greater Los Angeles Healthcare System
- Target Recruit Count
- 23
- Registration Number
- NCT00304421
- Locations
- 🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath